Díaz GEJ, Regules SS, Santibañez SV, García ARS

Language: Spanish
References: 17
Page: 143-147
PDF size: 180.81 Kb.

ABSTRACT

Obesity is "the abnormal or excessive accumulation of fat that may be harmful to health". This is a public health problem that has increased its prevalence in recent decades, causing metabolic alterations that raise morbidity and mortality. Currently, the World Health Organization's definition of obesity refers to an excessive accumulation or abnormal distribution of body fat that affects health. Before 1990, various drugs were prescribed to treat obesity, such as dinitrophenol, amphetamines, and phentermine, among others; unfortunately, these drugs lacked studies supporting their effectiveness and were withdrawn from the market. The treatment of obesity should be approached based on the degree of obesity and the patient; lifestyle and diet modifications are essential in the treatment. Among the new therapies used is the use of retatrutide, a triple agonist of GLP-1/GIP/GCG receptors, whose effect reduces food intake and increases energy expenditure, promoting weight reduction along with improvement in glucose levels; however, it is still in phase 1B.

REFERENCES

1. Meneses-Sierra E, Ochoa-Martínez C, Burciaga-Jiménez E. Abordaje multidisciplinario del sobrepeso y la obesidad en adultos. Med Int Méx [Internet]. 2023; 39 (2): 329-366. Disponible en: https://www.medigraphic.com/pdfs/medintmex/mim-2023/mim232l.pdf

2. Perez-Campos E, Mayoral LC, Andrade G, Mayoral EC, Huerta T, Canseco S et al. Obesity subtypes, related biomarkers & heterogeneity. Indian J Med Res [Internet]. 2020; 151 (1): 11-21. Available in: http://dx.doi.org/10.4103/ijmr.ijmr_1768_17

3. Fitch AK, Bays HE. Obesity definition, diagnosis, bias, standard operating procedures (SOPs), and telehealth: an Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. Obesity Pillars [Internet]. 2022; 1: 100004. Available in: http://dx.doi.org/10.1016/j.obpill.2021.100004

4. Pavía-López AA, Alcocer-Gamba MA, Ruiz-Gastelum ED, Mayorga-Butrón JL, Mehta R, Díaz-Aragón FA et al. Guía de práctica clínica mexicana para el diagnóstico y tratamiento de las dislipidemias y enfermedad cardiovascular aterosclerótica. Arch Cardiol Mex [Internet]. 2022; 92 (Supl): 1-62. Disponible en: http://dx.doi.org/10.24875/acm.m22000081

5. Shamah-Levy T, Campos-Nonato I, Cuevas-Nasu L, Hernández-Barrera L, Morales-Ruán M del C, Rivera-Dommarco J et al. Sobrepeso y obesidad en población mexicana en condición de vulnerabilidad. Resultados de la Ensanut 100k. Salud Publica Mex [Internet]. 2019; 61 (6, nov-dic): 852-865. Disponible en: https://www.saludpublica.mx/index.php/spm/article/view/10585

6. Campos-Nonato I, Galván-Valencia O, en Nutr Pobl D, Hernández-Barrera L, en Epidem D, Oviedo-Solís C et al. Prevalencia de obesidad y factores de riesgo asociados en adultos mexicanos: resultados de la Ensanut 2022. Salud Pública de México [Internet]. 2023; 65: S238-S247. Disponible en: https://ensanut.insp.mx/encuestas/ensanutcontinua2022/doctos/analiticos/31-Obesidad.y.riesgo-ENSANUT2022-14809-72498-2-10-20230619.pdf

7. Wang L, Liu Y, Hu F, Zhou Z. The potential mechanisms of white adipose tissue browning: a novel target for the treatment of obesity. Nutr Hosp [Internet]. 2022; 39 (2): 411-424. Available in: https://www.nutricionhospitalaria.org/articles/03852/show#

8. Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet [Internet]. 2023; 402 (10401): 529-544. Available in: http://dx.doi.org/10.1016/s0140-6736(23)01053-x

9. Kaufer-Horwitz M, Carreto-Adán MG, Pérez-Hernández F. Perímetro de cuello y éxito del tratamiento de pacientes con obesidad: estudio de vida real. Gac Med Mex [Internet]. 2019; 155 (6): 596-601. Disponible en: https://www.gacetamedicademexico.com/files/gmm_19_155_6_596-601.pdf

10. Kaufer-Horwitz M, Pérez Hernández JF. La obesidad: aspectos fisiopatológicos y clínicos. Inter Disciplina [Internet]. 2022; 10 (26): 147-175. Disponible en: http://dx.doi.org/10.22201/ceiich.24485705e.2022.26.80973

11. Benaiges D, Pedro-Botet J, Flores-Le Roux JA, Climent E, Goday A. Pasado, presente y futuro de la farmacoterapia para la obesidad. Clin Investig Arterioscler [Internet]. 2017; 29 (6): 256-264. Disponible en: https://www.elsevier.es/es-revista-clinica-e-investigacion-arteriosclerosis-15-pdf-S0214916817300852

12. Salazar López R. La obesidad y su tratamiento a lo largo del tiempo. Rev Col Cirugía Plástica y Reconstructi [Internet]. 2020; 26 (1): 71-75. Disponible en: https://www.ciplastica.com/ojs/index.php/rccp/article/viewFile/138/pdf

13. Ruiz-Cota P, Bacardí-Gascón M, Jiménez-Cruz A. Historia, tendencias y causas de la obesidad en México. JONNPR [Internet]. 2019; 4 (7): 737-745. Disponible en: https://revistas.proeditio.com/jonnpr/article/view/HISTORIA

14. DOF - Diario Oficial de la Federación [Internet]. Gob.mx. [citado el 21 de diciembre de 2023]. Disponible en: https://www.dof.gob.mx/nota_detalle.php?codigo=5523105&fecha=18/05/2018

15. Kloock S, Ziegler CG, Dischinger U. Obesity and its comorbidities, current treatment options and future perspectives: Challenging bariatric surgery? Pharmacol Ther [Internet]. 2023; 251 (108549): 108549. Available in: http://dx.doi.org/10.1016/j.pharmthera.2023.108549

16. Dias S, Paredes S, Ribeiro L. Drugs involved in dyslipidemia and obesity treatment: Focus on adipose tissue. Int J Endocrinol [Internet]. 2018; 2018: 2637418. Available in: http://dx.doi.org/10.1155/2018/2637418

17. Genchi VA, Palma G, Sorice GP, D'Oria R, Caccioppoli C, Marrano N et al. Pharmacological modulation of adaptive thermogenesis: new clues for obesity management? J Endocrinol Invest [Internet]. 2023; 46 (11): 2213-2236. Available in: http://dx.doi.org/10.1007/s40618-023-02125-0